|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4700 AUD | -1.05% |
|
+11.90% | +9.30% |
| 09/03 | Island Pharmaceuticals Begins Strategic Collaboration With Australian Infectious Disease Research Organization | MT |
| 04/03 | Daily Special: Island Pharmaceuticals, GenusPlus Group, Horizon Gold | FI |
Company Valuation: Island Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7.721 | 9.761 | 33.05 | 140 | - | - |
| Change | - | 26.43% | 238.62% | 323.6% | - | - |
| Enterprise Value (EV) 1 | 7.721 | 8.523 | 33.05 | 140.6 | 121.8 | 397.6 |
| Change | - | 10.39% | 287.83% | 325.42% | -13.37% | 226.41% |
| P/E ratio | -2.94x | -2.43x | -6.19x | -26.8x | -10.1x | 0.47x |
| PBR | - | 6.42x | - | - | - | - |
| PEG | - | 1.29x | 0.2x | 1.2x | -0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | 0.28x |
| EV / Revenue | - | - | - | - | - | 0.8x |
| EV / EBITDA | - | -3.02x | - | -21.6x | -6.48x | 0.94x |
| EV / EBIT | - | -3.02x | - | -21.6x | -6.48x | 0.94x |
| EV / FCF | - | - | - | -16.9x | -6.48x | 1.44x |
| FCF Yield | - | - | - | -5.9% | -15.4% | 69.4% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0323 | -0.0317 | -0.0226 | -0.0177 | -0.047 | 1.011 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 500 |
| EBITDA 1 | - | -2.818 | - | -6.5 | -18.8 | 420.8 |
| EBIT 1 | - | -2.818 | - | -6.5 | -18.8 | 420.8 |
| Net income 1 | -2.83 | -2.864 | -3.92 | -4.6 | -13.2 | 294.7 |
| Net Debt 1 | - | -1.238 | - | 0.6 | -18.2 | 257.6 |
| Reference price 2 | 0.0950 | 0.0770 | 0.1400 | 0.4750 | 0.4750 | 0.4750 |
| Nbr of stocks (in thousands) | 81,268 | 126,767 | 236,093 | 294,767 | - | - |
| Announcement Date | 30/8/23 | 29/8/24 | 28/8/25 | - | - | - |
1AUD in Million2AUD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -27.68x | - | -22.31x | - | 103M | ||
| 42.74x | 10x | 36.07x | 0.03% | 44.8B | ||
| 15.94x | 5.69x | 12.52x | 1.88% | 40.35B | ||
| -51.84x | 17.45x | -57.65x | -.--% | 30.05B | ||
| -17.5x | 4.48x | -8.41x | -.--% | 21.8B | ||
| 27.64x | 5.7x | 15.82x | -.--% | 19.09B | ||
| 22.04x | 4.19x | 13.68x | -.--% | 16.72B | ||
| -329.09x | 27.33x | 1504.74x | -.--% | 13.53B | ||
| -14.2x | 6349.59x | -18.15x | -.--% | 12.47B | ||
| -169.65x | 41.3x | -164.02x | -.--% | 12.1B | ||
| Average | -50.16x | 718.41x | 131.23x | 0.21% | 21.1B | |
| Weighted average by Cap. | -24.50x | 386.49x | 89.45x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- ILA Stock
- Valuation Island Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















